CA2066645A1 - Methode de production de cellules lymphoides augmentees in vitro pour utilisation en immunotherapie adoptive - Google Patents

Methode de production de cellules lymphoides augmentees in vitro pour utilisation en immunotherapie adoptive

Info

Publication number: CA2066645A1
Authority: CA; Canada
Prior art keywords: cells; bioreactor; medium; fiber space; lymphoid cells
Prior art date: 1989-09-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002066645A

Other languages

English (en)

Inventor

Richard A. Knazek

William R. Kidwell

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Cellco Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-09-14

Filing date

1990-09-11

Publication date

1991-03-15

1990-09-11 Application filed by Individual filed Critical Individual

1991-03-15 Publication of CA2066645A1 publication Critical patent/CA2066645A1/fr

Status Abandoned legal-status Critical Current

Links

210000004698 lymphocyte Anatomy 0.000 title claims abstract description 137
238000000034 method Methods 0.000 title claims abstract description 89
238000000338 in vitro Methods 0.000 title claims abstract description 53
238000009169 immunotherapy Methods 0.000 title claims abstract description 41
238000004519 manufacturing process Methods 0.000 title claims description 11
210000004027 cell Anatomy 0.000 claims abstract description 348
239000000835 fiber Substances 0.000 claims abstract description 91
230000012010 growth Effects 0.000 claims abstract description 76
206010028980 Neoplasm Diseases 0.000 claims abstract description 57
239000000126 substance Substances 0.000 claims abstract description 57
230000001737 promoting effect Effects 0.000 claims abstract description 44
238000012258 culturing Methods 0.000 claims abstract description 14
230000001225 therapeutic effect Effects 0.000 claims abstract description 9
239000012510 hollow fiber Substances 0.000 claims description 83
210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 80
239000002609 medium Substances 0.000 claims description 70
239000000427 antigen Substances 0.000 claims description 58
102000036639 antigens Human genes 0.000 claims description 58
108091007433 antigens Proteins 0.000 claims description 58
239000006228 supernatant Substances 0.000 claims description 36
230000010412 perfusion Effects 0.000 claims description 31
239000003104 tissue culture media Substances 0.000 claims description 30
238000003306 harvesting Methods 0.000 claims description 28
239000000725 suspension Substances 0.000 claims description 28
102000000588 Interleukin-2 Human genes 0.000 claims description 27
102000004127 Cytokines Human genes 0.000 claims description 26
108090000695 Cytokines Proteins 0.000 claims description 26
108010002350 Interleukin-2 Proteins 0.000 claims description 26
108090000623 proteins and genes Proteins 0.000 claims description 20
102000004169 proteins and genes Human genes 0.000 claims description 19
239000003636 conditioned culture medium Substances 0.000 claims description 17
230000000694 effects Effects 0.000 claims description 15
102000004388 Interleukin-4 Human genes 0.000 claims description 10
108090000978 Interleukin-4 Proteins 0.000 claims description 10
230000010261 cell growth Effects 0.000 claims description 7
210000004962 mammalian cell Anatomy 0.000 claims description 7
239000003226 mitogen Substances 0.000 claims description 6
102000004889 Interleukin-6 Human genes 0.000 claims description 5
108090001005 Interleukin-6 Proteins 0.000 claims description 5
230000032823 cell division Effects 0.000 claims description 5
102000000589 Interleukin-1 Human genes 0.000 claims description 4
108010002352 Interleukin-1 Proteins 0.000 claims description 4
239000003550 marker Substances 0.000 claims description 4
206010059866 Drug resistance Diseases 0.000 claims description 3
238000003780 insertion Methods 0.000 claims description 3
230000037431 insertion Effects 0.000 claims description 3
230000035945 sensitivity Effects 0.000 claims description 3
229940028885 interleukin-4 Drugs 0.000 claims 3
229940100601 interleukin-6 Drugs 0.000 claims 3
208000007660 Residual Neoplasm Diseases 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 14
201000011510 cancer Diseases 0.000 abstract description 13
208000026350 Inborn Genetic disease Diseases 0.000 abstract description 3
208000016361 genetic disease Diseases 0.000 abstract description 3
108010060889 Toll-like receptor 1 Proteins 0.000 description 30
210000004881 tumor cell Anatomy 0.000 description 27
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 17
239000008103 glucose Substances 0.000 description 17
210000003810 lymphokine-activated killer cell Anatomy 0.000 description 13
210000001519 tissue Anatomy 0.000 description 12
210000001744 T-lymphocyte Anatomy 0.000 description 11
108020004414 DNA Proteins 0.000 description 10
239000001963 growth medium Substances 0.000 description 10
238000011534 incubation Methods 0.000 description 10
102000008072 Lymphokines Human genes 0.000 description 9
108010074338 Lymphokines Proteins 0.000 description 9
235000015097 nutrients Nutrition 0.000 description 9
108091006905 Human Serum Albumin Proteins 0.000 description 8
102000008100 Human Serum Albumin Human genes 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
239000007789 gas Substances 0.000 description 8
230000000735 allogeneic effect Effects 0.000 description 7
238000004113 cell culture Methods 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
239000012636 effector Substances 0.000 description 7
108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
230000009089 cytolysis Effects 0.000 description 6
239000008367 deionised water Substances 0.000 description 6
229910021641 deionized water Inorganic materials 0.000 description 6
201000010099 disease Diseases 0.000 description 6
239000012737 fresh medium Substances 0.000 description 6
238000011081 inoculation Methods 0.000 description 6
239000000203 mixture Substances 0.000 description 6
239000000047 product Substances 0.000 description 6
230000009257 reactivity Effects 0.000 description 6
102000003390 tumor necrosis factor Human genes 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
102000029816 Collagenase Human genes 0.000 description 5
108060005980 Collagenase Proteins 0.000 description 5
102000016911 Deoxyribonucleases Human genes 0.000 description 5
108010053770 Deoxyribonucleases Proteins 0.000 description 5
108010003272 Hyaluronate lyase Proteins 0.000 description 5
102000001974 Hyaluronidases Human genes 0.000 description 5
102000015696 Interleukins Human genes 0.000 description 5
108010063738 Interleukins Proteins 0.000 description 5
239000012980 RPMI-1640 medium Substances 0.000 description 5
239000006285 cell suspension Substances 0.000 description 5
229960002424 collagenase Drugs 0.000 description 5
230000006378 damage Effects 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
238000007387 excisional biopsy Methods 0.000 description 5
229960002773 hyaluronidase Drugs 0.000 description 5
229940047122 interleukins Drugs 0.000 description 5
YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 5
210000001165 lymph node Anatomy 0.000 description 5
230000037361 pathway Effects 0.000 description 5
239000006152 selective media Substances 0.000 description 5
230000035899 viability Effects 0.000 description 5
230000000259 anti-tumor effect Effects 0.000 description 4
210000003719 b-lymphocyte Anatomy 0.000 description 4
210000004748 cultured cell Anatomy 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
239000012895 dilution Substances 0.000 description 4
239000003814 drug Substances 0.000 description 4
238000010353 genetic engineering Methods 0.000 description 4
239000011521 glass Substances 0.000 description 4
239000012528 membrane Substances 0.000 description 4
210000000822 natural killer cell Anatomy 0.000 description 4
239000008188 pellet Substances 0.000 description 4
238000010186 staining Methods 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
102000014150 Interferons Human genes 0.000 description 3
108010050904 Interferons Proteins 0.000 description 3
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
239000006143 cell culture medium Substances 0.000 description 3
239000003431 cross linking reagent Substances 0.000 description 3
230000001461 cytolytic effect Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000002054 inoculum Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
230000002101 lytic effect Effects 0.000 description 3
210000002540 macrophage Anatomy 0.000 description 3
201000001441 melanoma Diseases 0.000 description 3
210000001616 monocyte Anatomy 0.000 description 3
238000010647 peptide synthesis reaction Methods 0.000 description 3
239000004033 plastic Substances 0.000 description 3
239000004417 polycarbonate Substances 0.000 description 3
238000012545 processing Methods 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
239000004945 silicone rubber Substances 0.000 description 3
239000002002 slurry Substances 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
241001529936 Murinae Species 0.000 description 2
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000011324 bead Substances 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
229910052804 chromium Inorganic materials 0.000 description 2
239000011651 chromium Substances 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
230000009395 genetic defect Effects 0.000 description 2
210000002443 helper t lymphocyte Anatomy 0.000 description 2
230000028993 immune response Effects 0.000 description 2
230000001024 immunotherapeutic effect Effects 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000003993 interaction Effects 0.000 description 2
229940047124 interferons Drugs 0.000 description 2
230000002427 irreversible effect Effects 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
238000011031 large-scale manufacturing process Methods 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
238000011068 loading method Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
208000037819 metastatic cancer Diseases 0.000 description 2
208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
208000021039 metastatic melanoma Diseases 0.000 description 2
206010061289 metastatic neoplasm Diseases 0.000 description 2
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 2
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
239000002243 precursor Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
238000005086 pumping Methods 0.000 description 2
230000003134 recirculating effect Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
229920002379 silicone rubber Polymers 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
239000002699 waste material Substances 0.000 description 2
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
108010041397 CD4 Antigens Proteins 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
101100511454 Epichloe uncinata lolO1 gene Proteins 0.000 description 1
101100511455 Epichloe uncinata lolO2 gene Proteins 0.000 description 1
102000009024 Epidermal Growth Factor Human genes 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
208000036566 Erythroleukaemia Diseases 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000006354 HLA-DR Antigens Human genes 0.000 description 1
108010058597 HLA-DR Antigens Proteins 0.000 description 1
101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 1
101150083678 IL2 gene Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
108010050619 Monokines Proteins 0.000 description 1
102000013967 Monokines Human genes 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
241001503951 Phoma Species 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
229920013632 Ryton Polymers 0.000 description 1
239000004736 Ryton® Substances 0.000 description 1
108010008038 Synthetic Vaccines Proteins 0.000 description 1
102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
241000307523 Xenostegia media Species 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
208000021841 acute erythroid leukemia Diseases 0.000 description 1
238000013019 agitation Methods 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
229940047120 colony stimulating factors Drugs 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000000959 cryoprotective effect Effects 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
238000012921 fluorescence analysis Methods 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000005484 gravity Effects 0.000 description 1
238000012787 harvest procedure Methods 0.000 description 1
239000008241 heterogeneous mixture Substances 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
239000002523 lectin Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
229920002529 medical grade silicone Polymers 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
239000013618 particulate matter Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
229960003531 phenolsulfonphthalein Drugs 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920000098 polyolefin Polymers 0.000 description 1
-1 polypropylene Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
230000017363 positive regulation of growth Effects 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
238000001878 scanning electron micrograph Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000007858 starting material Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
210000002978 thoracic duct Anatomy 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M21/00—Bioreactors or fermenters specially adapted for specific uses
- C12M21/08—Bioreactors or fermenters specially adapted for specific uses for producing artificial tissue or for ex-vivo cultivation of tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/10—Hollow fibers or tubes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
- C12M29/10—Perfusion
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
- C12M29/16—Hollow fibers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Sustainable Development (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Hematology (AREA)
Cell Biology (AREA)
Molecular Biology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CA002066645A 1989-09-14 1990-09-11 Methode de production de cellules lymphoides augmentees in vitro pour utilisation en immunotherapie adoptive Abandoned CA2066645A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US40745689A	1989-09-14	1989-09-14
US407,456		1989-09-14

Publications (1)

Publication Number	Publication Date
CA2066645A1 true CA2066645A1 (fr)	1991-03-15

Family

ID=23612175

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002066645A Abandoned CA2066645A1 (fr)	1989-09-14	1990-09-11	Methode de production de cellules lymphoides augmentees in vitro pour utilisation en immunotherapie adoptive

Country Status (5)

Country	Link
EP (1)	EP0491851A4 (fr)
JP (1)	JPH05502369A (fr)
AU (1)	AU652725B2 (fr)
CA (1)	CA2066645A1 (fr)
WO (1)	WO1991004317A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1992010564A1 (fr) *	1990-12-13	1992-06-25	The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce	Production soutenue et continue de titres eleves de vecteurs viraux recombines et cellules cibles obtenues par transduction utilisables dans des therapies genetiques
IT1261180B (it) *	1993-02-10	1996-05-09		Metodo di propagazione in vitro di cellule til.
ATE244300T1 (de)	1996-01-17	2003-07-15	Imp College Innovations Ltd	Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
DE10021627B4 (de)	2000-05-04	2009-11-19	Corlife Gbr (Vertretungsberechtigte Gesellschafter: Prof. Dr. Alex Haverich	Verfahren zur Herstellung eines vaskularisierten bioartifiziellen Gewebes und zugehöriger Versuchsreaktor
PT1408106E (pt) *	2002-10-11	2007-04-30	Sentoclone Ab	Imunoterapia de cancro
EP1479760A1 (fr) *	2003-05-19	2004-11-24	ProBioGen AG	Organe d'immunité artificielle
EP3294872B1 (fr) *	2015-05-13	2019-07-24	Terumo BCT, Inc.	Expansion cellulaire
CN108289912A (zh) *	2015-09-01	2018-07-17	先天肿瘤免疫公司	具有提高的免疫力或免疫抑制性细胞因子抗性的免疫细胞及其用途
EP3216861A1 (fr) *	2016-03-11	2017-09-13	Fropharm GmbH	Cellules immunorégulatrices et leurs procédés de production
KR20190045321A (ko) *	2016-09-12	2019-05-02	주노 쎄러퓨티크스 인코퍼레이티드	관류 생물 반응기 백 조립체
CN109536444B (zh) *	2018-12-11	2022-06-28	吉林省拓华生物科技有限公司	一种适用于恶性实体瘤肿瘤浸润t淋巴细胞的分离诱导方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3883393A (en) *	1972-05-18	1975-05-13	Us Health Education & Welfare	Cell culture on semi-permeable tubular membranes
JPS5642584A (en) *	1979-09-18	1981-04-20	Asahi Chem Ind Co Ltd	Cell cultivation method
US4690915A (en) *	1985-08-08	1987-09-01	The United States Of America As Represented By The Department Of Health And Human Services	Adoptive immunotherapy as a treatment modality in humans
ATE82588T1 (de) *	1986-04-28	1992-12-15	Endotronics Inc	Zuchtverfahren fuer leukocyten.
EP0475972A4 (en) *	1989-05-15	1992-05-20	E.I. Du Pont De Nemours And Company	Improved culture of human tumor-infiltrating lymphocytes by combining gas permeable bags and a primary culture container

1990
- 1990-09-11 AU AU65008/90A patent/AU652725B2/en not_active Ceased
- 1990-09-11 CA CA002066645A patent/CA2066645A1/fr not_active Abandoned
- 1990-09-11 WO PCT/US1990/005051 patent/WO1991004317A1/fr not_active Ceased
- 1990-09-11 JP JP2513730A patent/JPH05502369A/ja active Pending
- 1990-09-11 EP EP19900914826 patent/EP0491851A4/en not_active Withdrawn

Also Published As

Publication number	Publication date
EP0491851A1 (fr)	1992-07-01
JPH05502369A (ja)	1993-04-28
AU652725B2 (en)	1994-09-08
EP0491851A4 (en)	1993-02-17
WO1991004317A1 (fr)	1991-04-04
AU6500890A (en)	1991-04-18

Publication	Publication Date	Title
KR100271284B1 (ko)	2000-11-01	사람의 스템 세포 및/또는 조혈세포를 유지하고 증식시키는 방법, 조성 및 장치
Knazek et al.	1990	Culture of human tumor infiltrating lymphocytes in hollow fiber bioreactors
US6835566B2 (en)	2004-12-28	Human lineage committed cell composition with enhanced proliferative potential, biological effector function, or both; methods for obtaining same; and their uses
ES2523366T3 (es)	2014-11-25	Uso de un dispositivo de filtración de flujo tangencial y métodos para el enriquecimiento de leucocitos
US5763266A (en)	1998-06-09	Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells
US7682822B2 (en)	2010-03-23	Ex vivo generated tissue system
EP1625212B1 (fr)	2007-08-22	Organe d'immunite artificielle
EP0302894A1 (fr)	1989-02-15	Procede de culture de leucocytes.
JPH078274A (ja)	1995-01-13	膜バイオリアクター中の物質移動を改良する方法及び装置
EP0614485A1 (fr)	1994-09-14	Methodes pour la multiplication selective de cellules-souches
AU652725B2 (en)	1994-09-08	Method for the production of in vitro expanded lymphoid cells for use in adoptive immunotherapy
CN112662626A (zh)	2021-04-16	一种脐带间充质干细胞共培养自然杀伤细胞的方法
US7179643B2 (en)	2007-02-20	Device and a process for expansion of haemopoeitic stem cells for therapeutic use
US12264308B2 (en)	2025-04-01	System and methods for immune cells expansion and activation in large scale
CN114686430A (zh)	2022-07-01	一种制备til的方法
WO1991018972A1 (fr)	1991-12-12	Culture de cellules de moelle osseuse utilisees en immunotherapie adoptive
CN111787929A (zh)	2020-10-16	细胞重编程疗法
Jelinek et al.	2002	Novel bioreactors for the ex vivo cultivation of hematopoietic cells
WO1995019793A1 (fr)	1995-07-27	Procede permettant l'expansion de cellules hematopoïetiques et procedes de greffe associes
Nordon et al.	1996	Ex vivo manipulation of cell subsets for cell therapies
Shankar et al.	1997	Retroviral transduction of peripheral blood leukocytes in a hollow‐fiber bioreactor
CN114958740A (zh)	2022-08-30	体外培养富集人nk细胞的方法
Henschler et al.	1997	Ex Vivo Culture and Expansion of Haematopoietic Progenitor Cells in Cancer Patients
Highfill	1995	Development and implementation of a large-scale bioreactor system for the cultivation of murine bone marrow cells
JP2002171967A (ja)	2002-06-18	造血細胞群の体外培養方法

Legal Events

Date	Code	Title	Description
1997-09-11	FZDE	Discontinued